191 related articles for article (PubMed ID: 22520146)
1. Long-term control of a MEN1 prolactin secreting pituitary carcinoma after temozolomide treatment.
Philippon M; Morange I; Barrie M; Barlier A; Taieb D; Dufour H; Conte-Devolx B; Brue T; Castinetti F
Ann Endocrinol (Paris); 2012 Jun; 73(3):225-9. PubMed ID: 22520146
[TBL] [Abstract][Full Text] [Related]
2. Failure of a second temozolomide cycle in a patient with a prolactin-secreting pituitary carcinoma.
Bilbao I; Egaña N; García C; Olaizola I
Endocrinol Diabetes Nutr; 2017 Dec; 64(10):564-566. PubMed ID: 29137963
[No Abstract] [Full Text] [Related]
3. A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report.
Murakami M; Mizutani A; Asano S; Katakami H; Ozawa Y; Yamazaki K; Ishida Y; Takano K; Okinaga H; Matsuno A
Neurosurgery; 2011 Jun; 68(6):E1761-7; discussion E1767. PubMed ID: 21389894
[TBL] [Abstract][Full Text] [Related]
4. Long-term response of pituitary carcinoma to temozolomide. Report of two cases.
Fadul CE; Kominsky AL; Meyer LP; Kingman LS; Kinlaw WB; Rhodes CH; Eskey CJ; Simmons NE
J Neurosurg; 2006 Oct; 105(4):621-6. PubMed ID: 17044568
[TBL] [Abstract][Full Text] [Related]
5. Temozolomide retreatment in a recurrent prolactin-secreting pituitary adenoma: Hormonal and radiographic response.
Strowd RE; Salvatori R; Laterra JJ
J Oncol Pharm Pract; 2016 Jun; 22(3):517-22. PubMed ID: 25616657
[TBL] [Abstract][Full Text] [Related]
6. Evolution of a prolactin-secreting pituitary microadenoma into a fatal carcinoma: a case report.
Guastamacchia E; Triggiani V; Tafaro E; De Tommasi A; De Tommasi C; Luzzi S; Sabbà C; Resta F; Terreni MR; Losa M
Minerva Endocrinol; 2007 Sep; 32(3):231-6. PubMed ID: 17912159
[TBL] [Abstract][Full Text] [Related]
7. SOM230 (pasireotide) and temozolomide achieve sustained control of tumour progression and ACTH secretion in pituitary carcinoma with widespread metastases.
Bode H; Seiz M; Lammert A; Brockmann MA; Back W; Hammes HP; Thomé C
Exp Clin Endocrinol Diabetes; 2010 Nov; 118(10):760-3. PubMed ID: 20496311
[TBL] [Abstract][Full Text] [Related]
8. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience.
Raverot G; Sturm N; de Fraipont F; Muller M; Salenave S; Caron P; Chabre O; Chanson P; Cortet-Rudelli C; Assaker R; Dufour H; Gaillard S; François P; Jouanneau E; Passagia JG; Bernier M; Cornélius A; Figarella-Branger D; Trouillas J; Borson-Chazot F; Brue T
J Clin Endocrinol Metab; 2010 Oct; 95(10):4592-9. PubMed ID: 20660056
[TBL] [Abstract][Full Text] [Related]
9. Novel Germline p.Gly42Val
Koehler VF; Jungheim K; Groß U; Iacovazzo D; Mann A; Korbonits M
Ann Clin Lab Sci; 2017 Sep; 47(5):606-610. PubMed ID: 29066490
[TBL] [Abstract][Full Text] [Related]
10. Successful treatment of a child with a prolactin secreting macroadenoma with temozolomide.
Felker J; Patterson B; Wrubel D; Janss A
J Pediatr Endocrinol Metab; 2016 Dec; 29(12):1413-1415. PubMed ID: 27815961
[TBL] [Abstract][Full Text] [Related]
11. Early Recognition and Initiation of Temozolomide Chemotherapy for Refractory, Invasive Pituitary Macroprolactinoma with Long-Term Sustained Remission.
Barkhoudarian G; Palejwala SK; Ogunbameru R; Wei H; Eisenberg A; Kelly DF
World Neurosurg; 2018 Oct; 118():118-124. PubMed ID: 30031177
[TBL] [Abstract][Full Text] [Related]
12. [Pituitary melanocytoma mimicking an adenoma].
Coulibaly B; Bouvier C; Paula AM; Fernandez C; Dufour H; Figarella-Branger D
Ann Pathol; 2011 Feb; 31(1):50-2. PubMed ID: 21349390
[TBL] [Abstract][Full Text] [Related]
13. Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists.
Neff LM; Weil M; Cole A; Hedges TR; Shucart W; Lawrence D; Zhu JJ; Tischler AS; Lechan RM
Pituitary; 2007; 10(1):81-6. PubMed ID: 17285366
[TBL] [Abstract][Full Text] [Related]
14. Multiple endocrine neoplasia type 1.
Marini F; Falchetti A; Del Monte F; Carbonell Sala S; Gozzini A; Luzi E; Brandi ML
Orphanet J Rare Dis; 2006 Oct; 1():38. PubMed ID: 17014705
[TBL] [Abstract][Full Text] [Related]
15. Temozolomide therapy for resistant prolactin-secreting pituitary adenomas and carcinomas: a systematic review.
Almalki MH; Aljoaib NN; Alotaibi MJ; Aldabas BS; Wahedi TS; Ahmad MM; Alshahrani F
Hormones (Athens); 2017 Apr; 16(2):139-149. PubMed ID: 28742502
[TBL] [Abstract][Full Text] [Related]
16. The role of temozolomide in the treatment of a patient with a pure silent pituitary somatotroph carcinoma.
Vieira Neto L; Chimelli L; Pereira PJ; Gasparetto EL; Bines J; Wildemberg LE; Gadelha MR
Endocr Pract; 2013; 19(6):e145-9. PubMed ID: 23807517
[TBL] [Abstract][Full Text] [Related]
17. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia.
Colao A; Di Sarno A; Cappabianca P; Di Somma C; Pivonello R; Lombardi G
N Engl J Med; 2003 Nov; 349(21):2023-33. PubMed ID: 14627787
[TBL] [Abstract][Full Text] [Related]
18. Temozolomide: a novel treatment for pituitary carcinoma.
Lim S; Shahinian H; Maya MM; Yong W; Heaney AP
Lancet Oncol; 2006 Jun; 7(6):518-20. PubMed ID: 16750503
[No Abstract] [Full Text] [Related]
19. Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas.
Lasolle H; Cortet C; Castinetti F; Cloix L; Caron P; Delemer B; Desailloud R; Jublanc C; Lebrun-Frenay C; Sadoul JL; Taillandier L; Batisse-Lignier M; Bonnet F; Bourcigaux N; Bresson D; Chabre O; Chanson P; Garcia C; Haissaguerre M; Reznik Y; Borot S; Villa C; Vasiljevic A; Gaillard S; Jouanneau E; Assié G; Raverot G
Eur J Endocrinol; 2017 Jun; 176(6):769-777. PubMed ID: 28432119
[TBL] [Abstract][Full Text] [Related]
20. Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: Morphological findings.
Kovacs K; Horvath E; Syro LV; Uribe H; Penagos LC; Ortiz LD; Fadul CE
Hum Pathol; 2007 Jan; 38(1):185-9. PubMed ID: 17056093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
